Abstract
Purpose: The 2017 publication of the ASCENDE-RT Trial demonstrated the efficacy of trimodality treatment in high-risk prostate cancer patients. Despite superior biochemical progression-free survival (b-PFS), the treatment was associated with higher GI and GU toxicities compared to external beam alone. We analyzed patients treated in a similar manner in Kelowna in the years following accrual to ASCENDE-RT to see if outcomes and toxicity rates remain comparable outside a clinical trial selected population.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
